Obstetric antiphospholipid syndrome: Early variations of angiogenic factors are associated with adverse outcomes

Haematologica

Volumn 102, Issue 5, 2017, Pages 835-842

  Cochery Nouvellon, Éva ^a,b   Mercier, Érick ^a,b,c   Bouvier, Sylvie ^a,b,c   Balducchi, Jean Pierre ^a   Quéré, Isabelle ^b,d   Perez Martin, Antonia ^a,b   Mousty, Eve ^a   Letouzey, Vincent ^a   Gris, Jean Christophe ^a,b,c  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b University of Montpellier 1   (France)

^c UNIV MONTPELLIER   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ENOXAPARIN; FMS LIKE TYROSINE KINASE 1; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADULT; ADVERSE OUTCOME; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHROMOSOME ABERRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS DEATH; FETUS WASTAGE; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; NEWBORN DEATH; PREECLAMPSIA; PREGNANCY OUTCOME; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; THROMBOCYTE COUNT; ADOLESCENT; BLOOD; CLINICAL TRIAL; FIRST TRIMESTER PREGNANCY; METABOLISM; PLACENTA; PREGNANCY; PREGNANCY COMPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MEMBRANE PROTEINS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 85018972413     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.155184     Document Type: Article

References (33)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-1311.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
3. Ruiz-Irastorza G, Crowther M, Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-509.
4. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009; 113(5):985-994.
5. de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13(8):795-813.
6. Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009;114(10):2020-2030.
7. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood. 2014; 123(3):404-413.
8. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-683.
9. Signore C, Mills JL, Qian C, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol. 2006; 108(2):338-344.
10. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316-1324.
11. Zygmunt M, Herr F, Münstedt K, Lang U, Liang OD. Angiogenesis and vasculogene-sis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;110(Suppl 1):S10-S18.
12. Rosenberg VA, Buhimschi IA, Lockwood CJ, et al. Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving antico-agulation therapy. Circulation. 2011; 124(23):2543-2553.
13. Yinon Y, Ben Meir E, Margolis L, et al. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor. Placenta. 2015;36(2):121-124.
14. Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214(1):108.e1-108.e14.
15. Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119(11):2624-2632.
16. Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-S22.
17. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;77(1):67-75.
18. [Estimation de la croissance neonatale et postnatale-Audipog.] Available at: www.audipog.net/module_ligne/php. Last accessed 13 March 2017.
19. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169(4):1000-1006.
20. Hagmann H, Bossung V, Belaidi AA, et al. Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination. PLoS One. 2014; 9(1):e85258.
21. Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10(5):279-289.
22. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293(1):77-85.
23. Weissgerber TL, Rajakumar A, Myerski AC, et al. Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy. J Clin Endocrinol Metab. 2014;99(3):978-987.
24. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108(9):1063-1070.
25. Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):77-82.
26. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost. 2006;4(11):2461-2469.
27. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000;84(5):742-746.
28. Smadja D, Gaussem P, Roncal C, Fischer AM, Emmerich J, Darnige L. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus. 2010;19(7):837-843.
29. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2007;2(3):543-549.
30. Carroll TY, Mulla MJ, Han CS, et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol. 2011;66(4):286-296.
31. Daugirdait V, van den Akker O, Purewal S. Posttraumatic stress and posttraumatic stress disorder after termination of pregnancy and reproductive loss: a systematic review. J Pregnancy. 2015;2015:646345.
32. Quenby S, Vince G, Farquharson R, Aplin J. Recurrent miscarriage: a defect in nature's quality control? Hum Reprod. 2002; 17(8):1959-1963.
33. Koot YE, Teklenburg G, Salker MS, Brosens JJ, Macklon NS. Molecular aspects of implantation failure. Biochim Biophys Acta. 2012;1822(12):1943-1950.